Rituxan Biosimilar Trials

With Rituxan's continued success and patent expiration approaching, many companies are counting the days until they can call this profitable drug their own. Rituxan's first noted success completely changed cancer treatment and today is used to treat chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and rheumatoid arthritis.

 Sandoz, the generic subsidiary of Novartis (NVS), is conducting a phase 3 trial for its compound GP2013, a biosimilar version of Rituxan used to treat patients with follicular lymphoma. A phase 1 trial has also begun to test the drug's use in treating Rheumatoid Arthritis (RA). Sandoz claims that in the past few years it has developed a robust, high-yield and large-scale process for the production of biosimilar Rituxan at its facilities in Schaftenau, Austria.  They are the only manufacturer to have more than two biosimilars on the market.

With the recent development and trials underway which pharmaceutical companies do you think will be the first to act on this biosimilar?

The Business of Biosimilars and Generic Drugs Summit will take place September 10-12 in Boston, MA. For more information on the speakers and presentations for this year's event, download the brochure. if you'd like to join us, register today and mention code XP1786BLOG to save 25% off the standard rate!

Share this article with your social network, just click below to share now!

Share |